The Next-Gen Arsenal of Genomic Tools for IRDs and Other Eye Diseases Lighting Up ARVO 2025
Innovative genomic techniques on display at ARVO 2025 could slam the door shut on some of the biggest challenges in…
FDA Grants RMAT Designation to Atsena Therapeutics’ Gene Therapy for X-linked Retinoschisis
The designation aims to expedite development of ATSN-201 for X-linked retinoschisis, a rare inherited retinal disease with no approved treatment.The…
popular posts
latest posts
